Grant ID RP210131
Awarded On August 18, 2021
Title Antibody-like therapeutics that target polyclonal T cells to CMV-positive glioblastomas
Program Academic Research
Award Mechanism High Impact/High Risk
Institution/Organization The University of Texas at Austin
Principal Investigator/Program Director Jennifer Maynard
Cancer Sites Brain and Other Nervous System
Contracted Amount $250,000*

*Pending contract negotiation

Lay Summary

Glioblastoma is a devastating brain tumor with no long-term cure. Current therapies rely on surgical resection, high-dose radiation and temozolomide chemotherapy, which significantly decrease patient quality of life and only provide a brief respite from disease. Immunotherapies could present a solution: antibodies and engineered T cells have demonstrated impressive clinical successes for some cancers, but a key challenge in GBM is identification of surface antigens that allow targeting of tumor but not healthy tissues. Notably, cytomegalovirus (CMV) proteins have been observed in >90% of glioblastomas but not healthy adjacent brain tissues, providing a possible means to target novel thera...

Read More